adrenocortical carcinoma

(redirected from Adrenal carcinoma)

adrenocortical carcinoma

Oncology A rare–≤ 2 in 106/yr tumor of the adrenal cortex; average age 46; ♂:♀ ratio 1:2.5 Clinical ± 70% of Pts with AC have endocrine symptoms due to excess secretion of glucocorticoids and/or androgens, less commonly due to excess mineralocorticoids or estrogens Management Surgical resection, mitotane. See Mitotane.
Adrenocortical cancer
Stage I
CA < 5 cms; no spread to periadrenal tissues
Stage II
CA > 5 cms; no spread to periadrenal tissues
Stage III
CA spread to periadrenal tissues or lymph nodes
Stage IV
CA spread to regional tissues or organs, to lymph nodes around adrenal cortex, or metastasized
.
References in periodicals archive ?
For this analysis, GlobalData epidemiologists used data available from Orphanet to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM.
The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing's disease, ectopic- adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
Primary adrenal carcinoma (ACC) is a rare, aggressive malignancy arising from the adrenal cortex.
The main differential diagnostic considerations are adenoma, metastasis, and solid masses, such as adrenal carcinoma and pheochromocytoma.
Even though many aggressive tumors such as adrenal carcinoma share some of these findings, diagnosis of GN should be considered in the presence of all or most of these findings (3).
Adrenal carcinoma is uncommon and accounts for approximately 0.
Biochemical Markers in a 64-Year-Old Woman with Metastatic Adrenal Carcinoma Laboratory Patient Established Measure Value Normal Values Potassium 2.
The panel chose to focus on what is known: that the overall risk of an incidentally found mass being a primary adrenal carcinoma appears to be about 0.
4 Metastatic adrenal carcinoma, sacral neuralgia Partial relief of neuropathic pelvic and perineal pain
The radiographic features of the adrenal lesion were consistent with primary adrenal carcinoma or possibly a metastasis from the renal primary.
Adrenal carcinoma with a signal loss on chemical shift magnetic resonance imaging.
The minor responses were seen in a patient with metastatic parotid cancer (21% reduction at 14 weeks) and a patient with metastatic adrenal carcinoma (18% reduction at 19 weeks).